Commission Delegated Regulation (EU) 2024/2564 of 19 June 2024 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

ANNEX
ANNEX
Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
(1)
the following entries are inserted following the consecutive order of the index numbers corresponding to each entry:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATE
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘005-022-00-4
perboric acid, sodium salt [1]
perboric acid, sodium salt, monohydrate [2]
perboric acid (HBO(O 2 )), sodium salt, monohydrate [3] sodium peroxoborate [4]
sodium perborate [5]
234-390-0 [1]
234-390-0 [2]
- [3]
- [4]
239-172-9 [5]
11138-47-9 [1]
12040-72-1 [2]
10332-33-9 [3]
- [4]
15120-21-5 [5]
Ox. Sol. 3
Repr. 1B
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Dam. 1
H272
H360FD
H331
H302
H335
H318
GHS03
GHS08
GHS06
GHS05
Dgr
H272
H360FD
H331
H302
H335
H318
inhalation: ATE = 0,75 mg/L (dusts or mists)
oral: ATE = 890 mg/kg bw
Eye Dam. 1; H318:
C ≥ 22 %
Eye Irrit. 2; H319:
14 % ≤ C < 22 %
11’
‘005-023-00-X
perboric acid (H 3 BO 2 (O 2 )), monosodium salt trihydrate [1]
perboric acid, sodium salt, tetrahydrate [2]
perboric acid (HBO(O 2 )), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4]
239-172-9 [1]
234-390-0 [2]
- [3]
- [4]
13517-20-9 [1]
37244-98-7 [2]
10486-00-7 [3]
- [4]
Repr. 1B
Acute Tox. 4
STOT SE 3
Eye Dam. 1
H360FD
H332
H335
H318
GHS08
GHS05
GHS07
Dgr
H360FD
H332
H335
H318
inhalation: ATE = 1,2 mg/L (dusts or mists)
Eye Dam. 1; H318: C ≥ 36 %
Eye Irrit. 2; H319: 22 % ≤ C < 36 %
11’
‘005-024-00-5
sodium peroxometaborate
231-556-4
7632-04-4
Ox. Sol. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Dam. 1
H272
H360FD
H331
H302
H335
H318
GHS03
GHS08
GHS06
GHS05
Dgr
H272
H360FD
H331
H302
H335
H318
inhalation: ATE = 0,62 mg/L (dusts or mists)
oral: ATE = 730 mg/kg bw
Eye Dam. 1; H318:
C ≥ 22 %
Eye Irrit. 2; H319: 14 % ≤ C < 22 %
11’
‘006-104-00-2
multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T
—
—
Carc. 1B
STOT RE 1
H350i
H372 (lung)(inhalation)
GHS08
Dgr
H350i
H372 (lung)(inhalation)
STOT RE 1; H372: C ≥ 1 %;
STOT RE 2; H373: 0,1 % ≤ C < 1 %’
‘029-026-00-0
copper [specific surface area > 0,67 mm 2 /mg]
231-159-6
7440-50-8
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 10
M = 1’
‘047-004-00-9
silver massive: [particle diameter ≥ 1 mm]
231-131-3
7440-22-4
Repr. 2
STOT RE 2
H361f
H373 (nervous system)
GHS08
Wng
H361f
H373 (nervous system)’
‘047-005-00-4
silver powder: [particle diameter > 100 nm < 1 mm]
231-131-3
7440-22-4
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H361f
H373 (nervous system)
H400
H410
GHS08
GHS09
Wng
H361f
H373 (nervous system)
H410
M = 10
M = 10’
‘047-006-00-X
silver nano: [particle diameter > 1 nm ≤ 100 nm]
231-131-3
7440-22-4
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H361f
H373 (nervous system)
H400
H410
GHS08
GHS09
Wng
H361f
H373 (nervous system)
H410
M = 1 000
M = 1 000 ’
‘603-247-00-8
reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol
—
—
Repr. 1B
H360Df
GHS08
Dgr
H360Df’
‘605-042-00-9
α-methyl-1,3-benzodioxole-5-propionaldehyde [1]
( S )-α-methyl-1,3-benzodioxole-5-propionaldehyde;
(2 S )-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2]
( R )-α-methyl-1,3-benzodioxole-5-propionaldehyde;
(2 R )-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3]
214-881-6 [1]
- [2]
- [3]
1205-17-0 [1]
737776-68-0 [2]
737776-59-9 [3]
Skin Sens. 1B
H317
GHS07
Wng
H317’
‘605-043-00-4
2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1]
(1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2]
2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3]
3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4]
3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5]
4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6]
reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7]
dimethylcyclohex-3-ene-1-carbaldehyde [8]
Dimethylcyclohex-3-ene-1-carbaldehyde [9]
1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10]
1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11]
2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12]
2,4,6-trimethylcyclohex-3-enecarbaldehyde [13]
isocyclocitral [14]
3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15]
4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16]
268-264-1 [1]
252-395-6 [2]
- [3]
268-263-6 [4]
267-186-5 [5]
253-139-6 [6]
- [7]
248-742-6 [8]
272-113-5 [9]
276-055-1 [10]
- [11]
- [12]
215-833-7 [13]
215-638-7 [14]
266-810-3 [15]
- [16]
68039-49-6 [1]
35145-02-9 [2]
6975-94-6 [3]
68039-48-5 [4]
67801-65-4 [5]
36635-35-5 [6]
- [7]
27939-60-2 [8]
68737-61-1 [9]
71832-78-5 [10]
40702-26-9 [11]
1726-47-2 [12]
1423-46-7 [13]
1335-66-6 [14]
67634-07-5 [15]
6754-27-4 [16]
Skin Sens. 1
H317
GHS07
Wng
H317’
‘606-156-00-1
acetone oxime
204-820-1
127-06-0
Carc. 1B
Acute Tox. 4
STOT SE 3
STOT RE 2
Eye Dam. 1
Skin Sens. 1
H350
H312
H336
H373 (blood system)
H318
H317
GHS08
GHS07
GHS05
Dgr
H350
H312
H336
H373 (blood system)
H318
H317
dermal: ATE = 1 100 mg/kg bw’
‘606-157-00-7
(3 E )-dec-3-en-2-one
—
18402-84-1
Acute Tox. 4
Asp. Tox. 1
Skin Irrit. 2
Aquatic Chronic 2
H332
H304
H315
H411
GHS07
GHS08
GHS09
Dgr
H332
H304
H315
H411
EUH071
inhalation: ATE = 1,5 mg/L (dusts or mists)’
‘606-158-00-2
2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one
438-340-0
119344-86-4
Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360Df
H400
H410
GHS08
GHS09
Dgr
H360Df
H410
M = 1
M = 1’
‘607-770-00-2
2,3-epoxypropyl neodecanoate
247-979-2
26761-45-5
Muta. 2
Skin Sens. 1A
H341
H317
GHS08
GHS07
Wng
H341
H317
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘607-771-00-8
benthiavalicarb-isopropyl (ISO); isopropyl [( S )-1-{[( R )-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate
—
177406-68-7
Carc. 1B
Repr. 2
Skin Sens. 1
Aquatic Chronic 2
H350
H361fd
H317
H411
GHS08
GHS07
GHS09
Dgr
H350
H361fd
H317
H411’
‘607-772-00-3
hexyl salicylate
228-408-6
6259-76-3
Repr. 2
Skin Sens. 1
H361d
H317
GHS08
GHS07
Wng
H361d
H317’
‘607-773-00-9
7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate
219-207-4
2386-87-0
Muta. 2
STOT RE 2
Skin Sens. 1
H341
H373 (nasal cavity)
H317
GHS08
GHS07
Wng
H341
H373 (nasal cavity)
H317’
‘607-774-00-4
tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1]
Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2]
disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3]
241-164-5 [1]
- [2]
- [3]
17095-24-8 [1]
- [2]
100556-82-9 [3]
Resp. Sens. 1A
Skin Sens. 1
H334
H317
GHS08
Dgr
H334
H317’
‘607-775-00-X
Sodium 3-(allyloxy)-2-hydroxypropanesulphonate
258-004-5
52556-42-0
Repr. 1B
Eye Dam. 1
H360F
H318
GHS08
GHS05
Dgr
H360F
H318’
‘609-074-00-4
1,4-dichloro-2-nitrobenzene
201-923-3
89-61-2
Carc. 1B
H350
GHS08
Dgr
H350’
‘611-182-00-1
2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol
271-183-4
68516-81-4
Skin Sens. 1A
H317
GHS07
Wng
H317
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘612-299-00-0
fenpropidin (ISO); ( R , S )-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine
—
67306-00-7
Repr. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT SE 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H361d
H332
H302
H335
H336
H373 (nervous system, eyes, lungs)
H315
H318
H317
H400
H410
GHS08
GHS07
GHS05
GHS09
Dgr
H361d
H332
H302
H335
H336
H373 (nervous system, eyes, lungs)
H315
H318
H317
H410
Inhalation: ATE = 1,2 mg/L (dusts or mists)
oral: ATE = 1 330 mg/kg bw
M = 1 000
M = 10 000 ’
‘613-350-00-X
1 H -benzotriazole
202-394-1
95-14-7
Aquatic Chronic 2
H411
GHS09
Wng
H411’
‘613-351-00-5
methyl-1 H -benzotriazole
249-596-6
29385-43-1
Aquatic Chronic 2
H411
GHS09
Wng
H411’
‘616-243-00-6
N,N' -methylenediacrylamide
203-750-9
110-26-9
Muta. 1B
H340
GHS08
Dgr
H340’
‘617-024-00-8
tert -butyl 2-ethylperoxyhexanoate
221-110-7
3006-82-4
Repr. 1B
Skin Sens. 1
H360FD
H317
GHS08
GHS07
Dgr
H360FD
H317’
(2)
the entries corresponding to index numbers 005-005-00-1, 016-022-00-9, 016-094-00-1, 029-019-01-X, 601-037-00-0, 604-020-00-6, 605-001-00-5, 607-001-00-0, 607-043-00-X, 607-094-00-8, 607-198-00-3, 607-315-00-8, 607-432-00-4, 613-272-00-6, 616-127-00-5 and 617-008-00-0 are replaced by the following entries respectively:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATE
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘005-005-00-1
trimethyl borate
204-468-9
121-43-7
Flam. Liq. 3
Repr. 1B
Acute Tox. 4*
H226
H360FD
H312
GHS02
GHS08
GHS07
Dgr
H226
H360FD
H312
11’
‘016-022-00-9
ethanethiol;
ethyl mercaptan
200-837-3
75-08-1
Flam. Liq. 1
Acute Tox. 3
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H224
H331
H302
H400
H410
GHS02
GHS06
GHS09
Dgr
H224
H331
H302
H410
inhalation: ATE = 7,1 mg/L (vapours)
oral: ATE = 680 mg/kg bw’
‘016-094-00-1
sulfur
231-722-6
7704-34-9
Skin Irrit. 2
H315
GHS07
Wng
H315’
‘029-019-01-X
copper flakes (coated with aliphatic acid)
Acute Tox. 3 Acute Tox. 4
Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1
H331
H302
H319
H400
H410
GHS06
GHS09
Dgr
H331
H302
H319
H410
inhalation: ATE = 0,733 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 1’
‘601-037-00-0
n -hexane
203-777-6
110-54-3
Flam. Liq. 2
Repr. 2
Asp. Tox. 1
STOT SE 3
STOT RE 1
Skin Irrit. 2
Aquatic Chronic 2
H225
H361f***
H304
H336
H372 (nervous system)
H315
H411
GHS02
GHS08
GHS07
GHS09
Dgr
H225
H361f***
H304
H336
H372 (nervous system)
H315
H411’
‘604-020-00-6
biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl
201-993-5
90-43-7
Carc. 2
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H351
H314
H318
H317
H400
H410
GHS08
GHS05
GHS07
GHS09
Dgr
H351
H314
H317
H410
M = 1
M = 1’
‘605-001-00-5
formaldehyde … %
200-001-8
50-00-0
Carc. 1B
Muta. 2
Acute Tox. 2
Acute Tox. 4
Skin Corr. 1B
Skin Sens. 1A
H350
H341
H330
H302
H314
H317
GHS08
GHS06
GHS05
Dgr
H350
H341
H330
H302
H314
H317
EUH071
inhalation: ATE = 100 ppmV (gases)
oral: ATE = 500 mg/kg bw
STOT SE 3; H335: C ≥ 5 %
Skin Corr. 1B; H314: C ≥ 25 %
Skin Irrit. 2; H315: 5 % ≤ C < 25 %
Eye Irrit. 2; H319: 5 % ≤ C < 25 %
B, D, F’
‘607-001-00-0
formic acid … %
200-579-1
64-18-6
Flam. Liq. 3
Met. Corr. 1
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1A
Eye Dam. 1
H226
H290
H331
H302
H314
H318
GHS02
GHS05
GHS06
Dgr
H226
H290
H331
H302
H314
EUH071
inhalation: ATE = 7,4 mg/L (vapours)
oral: ATE = 500 mg/kg bw
Flam. Liq. 3; H226: C > 85 %
Skin Corr. 1A; H314: C ≥ 90 %
Skin Corr. 1B; 314: 10 % ≤ C < 90 %
Skin Irrit. 2; H315: 2 % ≤ C < 10 %
Eye Dam. 1; H318: C ≥ 10 %
Eye Irrit. 2; H319: 2 % ≤ C < 10 %
B’
‘607-043-00-X
dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid
217-635-6
1918-00-9
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT SE 3
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 2
H332
H302
H335
H336
H318
H400
H411
GHS07
GHS05
GHS09
Dgr
H332
H302
H335
H336
H318
H410
inhalation: ATE = 4,0 mg/L (dusts or mists)
oral: ATE = 1 500 mg/kg bw
M = 1’
‘607-094-00-8
peracetic acid … %
201-186-8
79-21-0
Org. Perox. D
Acute Tox. 2
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1A
Aquatic Acute 1
Aquatic Chronic 1
H242
H330
H310
H301
H314
H400
H410
GHS02
GHS06
GHS05
GHS09
Dgr
H242
H330
H310
H301
H314
H410
EUH071
inhalation: ATE = 0,2 mg/L (dusts or mists)
dermal: ATE = 60 mg/kg bw
oral: ATE = 80 mg/kg bw
STOT SE 3; H335: C ≥ 1 %
M = 10
M = 100
B, D, T’
‘607-198-00-3
propyl 3,4,5-trihydroxybenzoate
204-498-2
121-79-9
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H317
H400
H410
GHS07
GHS09
Wng
H302
H317
H410
oral: ATE = 1 700 mg/kg bw
M = 1
M = 1’
‘607-315-00-8
glyphosate (ISO); N -(phosphonomethyl)glycine
213-997-4
1071-83-6
Eye Dam. 1
Aquatic Chronic 2
H318
H411
GHS05
GHS09
Dgr
H318
H411’
‘607-432-00-4
S -metolachlor (ISO); 2-chloro- N -(2-ethyl-6-methylphenyl)- N -[(2 S )-1-methoxypropan-2-yl]acetamide; ( R
a
S
a )-2-chloro- N -(6-ethyl- o -tolyl)- N -[(1 S )-2-methoxy-1-methylethyl]acetamide
[contains 80-100 % 2-chloro- N -(2-ethyl-6-methylphenyl)- N -[(2 S )-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro- N -(2-ethyl-6-methylphenyl)- N -[(2 R )-1-methoxypropan-2-yl]acetamide]
—
87392-12-9
Carc. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H317
H410
EUH066
M = 10
M = 10’
‘613-272-00-6
pyraclostrobin (ISO); methyl N -(2-{[1-(4-chlorophenyl)-1 H -pyrazol-3-yl]oxymethyl}phenyl) N -methoxy carbamate
—
175013-18-0
Repr. 2
Acute Tox. 3
Acute Tox. 4
STOT SE 3
STOT RE 2
Skin Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H331
H302
H335
H373 (liver, gastrointestinal tract, nasal cavity)
H315
H400
H410
GHS08
GHS06
GHS09
Dgr
H361d
H331
H302
H335
H373 (liver, gastrointestinal tract, nasal cavity)
H315
H410
inhalation: ATE = 0,58 mg/L (dusts or mists)
oral: ATE = 450 mg/kg bw
M = 100
M = 100’
‘616-127-00-5
reaction mass of N,N' -ethane-1,2-diylbis(decanamide) and 12-hydroxy- N -[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N' -ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1]
reaction mass of N,N' -ethane-1,2-diylbis(decanamide) and 12-hydroxy- N -[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2]
430-050-2 [1]
- [2]
- [1]
- [2]
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 100
M = 10’
‘617-008-00-0
dibenzoyl peroxide; benzoyl peroxide
202-327-6
94-36-0
Org. Perox. B
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H241
H319
H317
H400
H410
GHS01
GHS02
GHS07
GHS09
Dgr
H241
H319
H317
H410
M = 10
M = 10’
(3)
the entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 and 029-024-00-X are deleted.
Commission Delegated Regulation (EU) 2024/2564 of 19 June 2024 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

Schedules & Appendices

Cite this act
